169 related articles for article (PubMed ID: 19025355)
1. Molecular markers relating to malignant progression in Grade II astrocytoma.
Yue WY; Yu SH; Zhao SG; Chen ZP
J Neurosurg; 2009 Apr; 110(4):709-14. PubMed ID: 19025355
[TBL] [Abstract][Full Text] [Related]
2. Immunoexpression of tumor suppressor genes p53, p21 WAF1/CIP1 and p27 KIP1 in humam astrocystic tumors.
Faria MH; Patrocínio RM; Moraes Filho MO; Rabenhorst SH
Arq Neuropsiquiatr; 2007 Dec; 65(4B):1114-22. PubMed ID: 18345413
[TBL] [Abstract][Full Text] [Related]
3. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
Ständer M; Peraud A; Leroch B; Kreth FW
Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
[TBL] [Abstract][Full Text] [Related]
5. CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas.
Suren D; Isiksacan Ozen O
J BUON; 2013; 18(4):1006-11. PubMed ID: 24344030
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
[TBL] [Abstract][Full Text] [Related]
7. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features.
Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Hastazeris K; Salmas M; Stefanaki S; Agnantis NJ
Urol Int; 2004; 73(1):65-73. PubMed ID: 15263796
[TBL] [Abstract][Full Text] [Related]
8. Long-term molecular changes in WHO grade II astrocytomas following radiotherapy.
Yue WY; Sai K; Wu QL; Xia YF; Yu SH; Chen ZP
Chin J Cancer; 2012 Mar; 31(3):159-65. PubMed ID: 22313596
[TBL] [Abstract][Full Text] [Related]
9. Role of gemistocytes in astrocytoma progression.
Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic significance of cyclin A expression in low-grade astrocytomas: comparison with astrogliosis and high-grade tumours.
Hara A; Saegusa M; Ichinoe M; Okayasu I
J Clin Pathol; 2008 Mar; 61(3):287-92. PubMed ID: 18156430
[TBL] [Abstract][Full Text] [Related]
11. p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression.
van Meyel DJ; Ramsay DA; Casson AG; Keeney M; Chambers AF; Cairncross JG
J Natl Cancer Inst; 1994 Jul; 86(13):1011-7. PubMed ID: 8007011
[TBL] [Abstract][Full Text] [Related]
12. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.
Watanabe K; Sato K; Biernat W; Tachibana O; von Ammon K; Ogata N; Yonekawa Y; Kleihues P; Ohgaki H
Clin Cancer Res; 1997 Apr; 3(4):523-30. PubMed ID: 9815715
[TBL] [Abstract][Full Text] [Related]
13. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast.
Kleer CG; Giordano TJ; Braun T; Oberman HA
Mod Pathol; 2001 Mar; 14(3):185-90. PubMed ID: 11266524
[TBL] [Abstract][Full Text] [Related]
14. Tissue thioredoxin reductase-1 expression in astrocytomas of different grades.
Esen H; Erdi F; Kaya B; Feyzioglu B; Keskin F; Demir LS
J Neurooncol; 2015 Feb; 121(3):451-8. PubMed ID: 25391969
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival.
Hilton DA; Penney M; Evans B; Sanders H; Love S
Am J Surg Pathol; 2002 Apr; 26(4):472-8. PubMed ID: 11914625
[TBL] [Abstract][Full Text] [Related]
16. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays.
Terzi A; Saglam EA; Barak A; Soylemezoglu F
Pathol Res Pract; 2008; 204(5):305-14. PubMed ID: 18374497
[TBL] [Abstract][Full Text] [Related]
17. Recurrent astrocytic tumours--a study of p53 immunoreactivity and malignant progression.
Sarkar C; Ralte AM; Sharma MC; Mehta VS
Br J Neurosurg; 2002 Aug; 16(4):335-42. PubMed ID: 12389885
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of PCNA, Ki67, AgNOR and p53 expression in brain glial tumors].
Berny W; Weiser A; Markowska-Woyciechowska A; Jarmundowicz W; Zub W; Załuski R
Neurol Neurochir Pol; 2004; 38(6):457-63. PubMed ID: 15654669
[TBL] [Abstract][Full Text] [Related]
19. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value.
Cunningham JM; Kimmel DW; Scheithauer BW; O'Fallon JR; Novotny PJ; Jenkins RB
J Neurosurg; 1997 Jan; 86(1):121-30. PubMed ID: 8988090
[TBL] [Abstract][Full Text] [Related]
20. Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor.
Ishii N; Tada M; Hamou MF; Janzer RC; Meagher-Villemure K; Wiestler OD; Tribolet N; Van Meir EG
Oncogene; 1999 Oct; 18(43):5870-8. PubMed ID: 10557074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]